Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo), for the treatment of adults...
Ropeginterferon alfa-2b-njft treats essential thrombocythemia by targeting blood-forming cells in the bone marrow. The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) injection to treat adults with a rare blood cancer,...
Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo) for adult patients with polycythemia vera, a rare, slow-growing blood cancer that causes excessive blood...
Two zanidatamab-based regimens were approved for certain HER2-positive advanced gastric, gastroesophageal junction, or esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved zanidatamab-hrii (Ziihera) as part of two first-line treatment regimens for...
The new agent was approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone for patients with resistant or refractory disease. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to iberdomide (Zenbexus)...
Vusolimogene oderparepvec-wtpg and nivolumab earned accelerated approval to treat patients with advanced melanoma after PD-1 therapy. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev) in combination with...
Lutetium Lu 177 vipivotide tetraxetan is the first radioligand therapy approved for metastatic prostate cancer that responds to hormone treatment. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan...
Zidesamtinib, a next-generation ROS1 inhibitor, was approved for ROS1-positive NSCLC previously treated with ROS1 inhibition. The U.S. Food and Drug Administration (FDA) has approved zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for adults with locally...
Gedatolisib received its first FDA approval for advanced HR-positive, HER2-negative breast cancer without mutations in PIK3CA. The U.S. Food and Drug Administration (FDA) has approved gedatolisib (Revtorpyk) in combination with fulvestrant (Faslodex), with or...
The RET inhibitor received traditional approval to treat RET-fusion-positive solid tumors. The U.S. Food and Drug Administration (FDA) has granted full approval to selpercatinib (Retevmo) to treat RET-fusion-positive solid tumors in adult and pediatric...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More